Evidence map›Paper›PMID 35659195›Full record

ArticleAutophagy2023

Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy.

F Barutta, S Bellini, S Kimura, K Hase, B Corbetta, A Corbelli, F Fiordaliso, S Bruno, L Biancone, A Barreca and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Autophagy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 125 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

F BaruttaDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-9319-5123
S BelliniDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-2513-1651
S KimuraDivision of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan.
K HaseDivision of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan.
B CorbettaDepartment of Medical Sciences, University of Turin, Turin, Italy.
A CorbelliUnit of Bioimaging, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
F FiordalisoUnit of Bioimaging, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
S BrunoDepartment of Medical Sciences, University of Turin, Turin, Italy.
L BianconeDepartment of Medical Sciences, University of Turin, Turin, Italy.
A BarrecaDivision of Pathology, Città della Salute e della Scienza Hospital, Turin, Italy.
M G PapottiDepartment of Oncology, University of Turin, Turin, Italy.
E HirshDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-9073-6024
M MartiniDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-4262-946X
R GambinoDepartment of Medical Sciences, University of Turin, Turin, Italy.
M DurazzoDepartment of Medical Sciences, University of Turin, Turin, Italy.
H OhnoLaboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
G GrudenDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-8906-9589
University of Turin · ITKeio University · JPMario Negri Institute for Pharmacological Research · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITRIKEN Center for Integrative Medical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Podocyte injury leading to albuminuria is a characteristic feature of diabetic nephropathy (DN). Hyperglycemia and advanced glycation end products (AGEs) are major determinants of DN. However, the underlying mechanisms of podocyte injury remain poorly understood. The cytosolic protein TNFAIP2/M-Sec is required for tunneling nanotubes (TNTs) formation, which are membrane channels that transiently connect cells, allowing organelle transfer. Podocytes express TNFAIP2 and form TNTs, but the potential relevance of the TNFAIP2-TNT system in DN is unknown. We studied TNFAIP2 expression in both human and experimental DN and the renal effect of

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesPodocytesAlbuminuriaAnimalsAutophagyCell Membrane StructuresCytokinesGlucoseGlycation End Products, AdvancedHumansMiceNanotubesPhosphatidylinositol 3-KinasesStreptozocinTumor Necrosis FactorsCytokinesGlucoseGlycation End Products, AdvancedM-sec protein, mousePhosphatidylinositol 3-KinasesStreptozocinTNFAIP2 protein, humanTumor Necrosis FactorsTunneling NanotubesAdvanced glycation end productsalbuminuriaautophagosomesexperimental diabeteshyperglycemialysosomesnephrinpodocytesrenal function lossslit diaphragm

Identifiers

PMID35659195
PMCPMC9851239
OpenAlexW4281622500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.